Verona Pharma plc (NASDAQ:VRNA) CFO Mark W. Hahn Sells 80,784 Shares

Verona Pharma plc (NASDAQ:VRNA) CFO Mark W. Hahn sold 80,784 shares of the business’s stock in a transaction dated Monday, November 4th. The stock was sold at an average price of $4.39, for a total value of $354,641.76. Following the transaction, the chief financial officer now owns 14,293,736 shares of the company’s stock, valued at approximately $62,749,501.04. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Verona Pharma Stock Up 0.6 %

VRNA stock opened at $38.39 on Wednesday. The company has a debt-to-equity ratio of 0.72, a current ratio of 8.61 and a quick ratio of 8.61. Verona Pharma plc has a one year low of $11.39 and a one year high of $39.40. The company’s 50 day moving average price is $31.07 and its two-hundred day moving average price is $22.49.

Verona Pharma (NASDAQ:VRNA) last issued its earnings results on Monday, November 4th. The company reported ($0.56) EPS for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.12). The company had revenue of $5.62 million for the quarter, compared to the consensus estimate of $2.31 million. During the same quarter in the previous year, the firm posted ($0.18) EPS. Equities research analysts forecast that Verona Pharma plc will post -2.07 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of VRNA. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Verona Pharma by 25.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,610 shares of the company’s stock valued at $75,000 after acquiring an additional 529 shares during the period. GAMMA Investing LLC boosted its stake in shares of Verona Pharma by 70.6% during the third quarter. GAMMA Investing LLC now owns 1,336 shares of the company’s stock valued at $38,000 after purchasing an additional 553 shares during the period. CWM LLC purchased a new stake in shares of Verona Pharma during the second quarter valued at approximately $29,000. EMC Capital Management bought a new position in shares of Verona Pharma in the second quarter worth approximately $38,000. Finally, Sei Investments Co. increased its stake in shares of Verona Pharma by 3.7% in the first quarter. Sei Investments Co. now owns 74,294 shares of the company’s stock worth $1,195,000 after buying an additional 2,640 shares during the period. Hedge funds and other institutional investors own 85.88% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Canaccord Genuity Group boosted their price objective on Verona Pharma from $37.00 to $44.00 and gave the stock a “buy” rating in a report on Tuesday. Truist Financial boosted their price target on shares of Verona Pharma from $38.00 to $44.00 and gave the stock a “buy” rating in a research note on Wednesday, October 9th. Wells Fargo & Company raised their price objective on shares of Verona Pharma from $50.00 to $64.00 and gave the company an “overweight” rating in a research report on Tuesday. Finally, HC Wainwright upped their target price on shares of Verona Pharma from $36.00 to $42.00 and gave the stock a “buy” rating in a research report on Tuesday. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Verona Pharma has a consensus rating of “Buy” and a consensus price target of $43.83.

Verona Pharma Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.